FV/FII

Superficial and deep vein thrombosis and the resulting brain, lungs, coronary embolism is one of the most frequent causes of death in adults in the developed western countries. The potentially deadly disease is associated not only with lifestyle factors, but also with a genetic predisposition. More than half of thromboembolic events associated with genetic risk factors, the most important - factor V Leiden mutation and Factor II 20210G> A mutation causing increased blood clotting, and thus a higher risk of thrombosis. Individuals who are determined both mutations, venous thrombosis risk is 20 times higher than the general population.
The test is recommended for all persons with suspected inherited blood clotting. Available clinical expression of the disorder: deep venous thrombosis or venous thromboembolism in children under 50 years of age; unexplained blood clots in unusual places (liver, kidney, brain, intestines, eye veins); unexplained recurrent miscarriages, and others.

Test principle

The EUROArray is an in vitro test for molecular genetic determination of point mutations in the factor V gene (factor V Leiden mutation, 1691G>A) and/or the factor II (prothrombin) gene (20210G>A). EDTA blood (direct method) or extracted genomic DNA of the patient is used as sample material. In the direct method the blood is treated with the extraction solutions provided in the test system. In the first reaction step, a section of the factor V and a section of the factor II gene are amplified from the extract or, alternatively, from a genomic patient DNA sample using the polymerase chain reaction (PCR). The PCR products are labelled with a fl uorescence dye as they are produced. In the second reaction step, the products are analyzed using a microarray containing immobilized allele-specific probes, which are complementary to the amplified DNA, in the form of small, round spots. The binding (hybridization) of a fluorescing PCR product to its corresponding microarray spot is detected using the special Microarray Scanner (EUROIMMUN). All spot signals are automatically evaluated using the EUROArrayScan program. The genotype is determined for each parameter from the intensities of the signals originating from the allele-specific probes.

More information: www.euroimmun.com